Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats

Jorge F Giani1, Valeria Burghi, Luciana C Veiras

  • 1Facultad de Farmacia y Bioquímica, Instituto de Química y Fisicoquímica Biológicas, Universidad de Buenos Aires, Buenos Aires, Argentina.

Insights

Chronic treatment with Angiotensin (ANG)-(1-7) reduces kidney damage in Zucker diabetic fatty rats. This peptide therapy alleviates inflammation and oxidative stress, offering a potential new treatment for diabetic nephropathy.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic nephropathy is a significant complication of type 2 diabetes.
  • The precise mechanisms by which Angiotensin (ANG)-(1-7) impacts renal inflammation and oxidative stress in type 2 diabetes remain unclear.

Purpose of the Study:

  • To investigate the renoprotective effects of chronic ANG-(1-7) administration in Zucker diabetic fatty (ZDF) rats, a model of type 2 diabetes and nephropathy.
  • To evaluate the impact of ANG-(1-7) on renal inflammation and oxidative stress markers.

Main Methods:

  • ZDF rats and lean Zucker rats (LZR) received subcutaneous osmotic pumps delivering saline or ANG-(1-7) for two weeks.
  • Renal fibrosis, oxidative stress markers (thiobarbituric acid-reactive substances, superoxide dismutase, catalase), and inflammatory markers (interleukin-6, tumor necrosis factor-α, ED-1, hypoxia-inducible factor-1α, neutrophil gelatinase-associated lipocalin) were assessed.

Main Results:

  • ANG-(1-7) treatment in ZDF rats significantly reduced triglyceridemia, proteinuria, and systolic blood pressure, while restoring creatinine clearance.
  • A marked decrease in renal fibrosis and oxidative stress markers was observed.
  • Renal levels of key inflammatory markers (IL-6, TNF-α, ED-1, HIF-1α, NGAL) were significantly reduced to levels comparable to LZR.

Conclusions:

  • Chronic ANG-(1-7) treatment demonstrates significant renoprotective effects in ZDF rats.
  • The observed benefits are associated with reduced systolic blood pressure, oxidative stress, and inflammation.
  • ANG-(1-7) represents a promising therapeutic target for managing diabetic nephropathy.

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...